Penumbra, Inc. (NYSE:PEN) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. reduced its position in Penumbra, Inc. (NYSE:PEN) by 2.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 634,319 shares of the company’s stock after selling 13,634 shares during the quarter. Baillie Gifford & Co.’s holdings in Penumbra were worth $141,567,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Benjamin F. Edwards & Company Inc. grew its stake in shares of Penumbra by 171.8% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company’s stock worth $27,000 after purchasing an additional 67 shares during the period. Mather Group LLC. acquired a new position in shares of Penumbra during the 1st quarter worth $29,000. Signaturefd LLC grew its stake in shares of Penumbra by 27.2% during the 4th quarter. Signaturefd LLC now owns 215 shares of the company’s stock worth $54,000 after purchasing an additional 46 shares during the period. Quest Partners LLC acquired a new position in shares of Penumbra during the 4th quarter worth $71,000. Finally, Picton Mahoney Asset Management acquired a new position in shares of Penumbra during the 4th quarter worth $88,000. 88.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PEN has been the topic of a number of recent analyst reports. Canaccord Genuity Group lowered their price target on shares of Penumbra from $284.00 to $272.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. Truist Financial dropped their target price on shares of Penumbra from $290.00 to $280.00 and set a “buy” rating for the company in a report on Friday, March 22nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a report on Wednesday, May 8th. Finally, Piper Sandler lowered their price target on shares of Penumbra from $290.00 to $260.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 8th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $293.10.

Insiders Place Their Bets

In other news, CEO Adam Elsesser sold 15,000 shares of the company’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $200.98, for a total transaction of $3,014,700.00. Following the completion of the transaction, the chief executive officer now owns 942,582 shares of the company’s stock, valued at approximately $189,440,130.36. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Adam Elsesser sold 15,000 shares of the business’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $200.98, for a total transaction of $3,014,700.00. Following the completion of the sale, the chief executive officer now directly owns 942,582 shares of the company’s stock, valued at approximately $189,440,130.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Don W. Kassing sold 170 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $179.99, for a total value of $30,598.30. Following the sale, the director now owns 1,005 shares of the company’s stock, valued at $180,889.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,970 shares of company stock valued at $3,390,604. Insiders own 5.00% of the company’s stock.

Penumbra Trading Up 2.1 %

NYSE:PEN traded up $3.67 on Friday, reaching $181.09. The stock had a trading volume of 183,884 shares, compared to its average volume of 333,840. The company has a market cap of $7.02 billion, a price-to-earnings ratio of 76.45, a P/E/G ratio of 1.80 and a beta of 0.55. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.12 and a quick ratio of 3.51. The firm’s fifty day moving average is $191.79 and its two-hundred day moving average is $223.76. Penumbra, Inc. has a 12-month low of $170.59 and a 12-month high of $339.26.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, May 7th. The company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.01). The firm had revenue of $278.70 million during the quarter, compared to analysts’ expectations of $274.94 million. Penumbra had a net margin of 8.52% and a return on equity of 7.83%. Penumbra’s revenue for the quarter was up 15.5% on a year-over-year basis. During the same quarter last year, the company posted $0.23 earnings per share. Equities analysts expect that Penumbra, Inc. will post 2.87 EPS for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.